FR2843125B1 - Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs - Google Patents

Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs

Info

Publication number
FR2843125B1
FR2843125B1 FR0209905A FR0209905A FR2843125B1 FR 2843125 B1 FR2843125 B1 FR 2843125B1 FR 0209905 A FR0209905 A FR 0209905A FR 0209905 A FR0209905 A FR 0209905A FR 2843125 B1 FR2843125 B1 FR 2843125B1
Authority
FR
France
Prior art keywords
type
cosmetic
pharmaceutical compositions
human beta
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0209905A
Other languages
English (en)
Other versions
FR2843125A1 (fr
Inventor
Eric Perrier
Anne Guezennec
Ingrid Pernet
Corinne Reymernier
Joelle Guesnet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Beauty Care Solutions France SAS
YSL Beaute
Original Assignee
Coletica SA
YSL Beaute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coletica SA, YSL Beaute filed Critical Coletica SA
Priority to FR0209905A priority Critical patent/FR2843125B1/fr
Priority to DE10251709A priority patent/DE10251709C5/de
Priority to GB0225886A priority patent/GB2391476B/en
Priority to DE10262193.4A priority patent/DE10262193B4/de
Priority to US10/308,259 priority patent/US20040091493A1/en
Priority to KR1020020077561A priority patent/KR100697360B1/ko
Priority to JP2003006735A priority patent/JP4824901B2/ja
Publication of FR2843125A1 publication Critical patent/FR2843125A1/fr
Priority to JP2007208376A priority patent/JP5226257B2/ja
Priority to JP2012198441A priority patent/JP2012250992A/ja
Application granted granted Critical
Publication of FR2843125B1 publication Critical patent/FR2843125B1/fr
Priority to US15/248,195 priority patent/US20160361250A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/12—Face or body powders for grooming, adorning or absorbing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
FR0209905A 2002-08-02 2002-08-02 Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs Expired - Fee Related FR2843125B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR0209905A FR2843125B1 (fr) 2002-08-02 2002-08-02 Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs
DE10251709A DE10251709C5 (de) 2002-08-02 2002-11-06 Screening-Verfahren für Wirkstoffe zur Stimulierung der humanen beta-Defensine vom Typ 2 und/oder Typ 3
GB0225886A GB2391476B (en) 2002-08-02 2002-11-06 Use of active ingredients stimulating type 2 and/or type 3 human beta-defensins and cosmetic or pharmaceutical compositions containing such active ingredients
DE10262193.4A DE10262193B4 (de) 2002-08-02 2002-11-06 Kosmetische Verwendung eines Wirkstoffs zur Stimulierung der humanen beta-Defensine vom Typ 2 und/oder Typ 3, Verwendung eines solchen Wirkstoffs zur Herstellung einer pharmazeutischen Zusammensetzung, die einen solchen Wirkstoff enthält und Verwendung eines solchen Wirkstoffs auf dem Gebiet der Geweberekonstruktion
US10/308,259 US20040091493A1 (en) 2002-08-02 2002-11-25 Active ingredients stimulating type 2 and/or type 3 human beta-defensins and cosmetic or pharmaceutical compositions containing such active ingredients
KR1020020077561A KR100697360B1 (ko) 2002-08-02 2002-12-07 인간 유래 β-디펜신 타입 2 및/또는 타입 3의 유도활성성분 및 상기 활성성분을 포함하는 화장품 또는약학적 조성물
JP2003006735A JP4824901B2 (ja) 2002-08-02 2003-01-15 ２型又は３型ヒトβ−デフェンシンを刺激する活性成分とその活性成分を含有する化粧用組成物及び医薬組成物
JP2007208376A JP5226257B2 (ja) 2002-08-02 2007-08-09 ２型又は３型ヒトβ−デフェンシンを刺激する活性成分とその活性成分を含有する化粧用組成物及び医薬組成物
JP2012198441A JP2012250992A (ja) 2002-08-02 2012-09-10 ２型又は３型ヒトβ−デフェンシンを刺激する活性成分とその活性成分を含有する化粧用組成物及び医薬組成物
US15/248,195 US20160361250A1 (en) 2002-08-02 2016-08-26 Active ingredients stimulating type 2 and/or type 3 human beta-defensins and cosmetic or pharmaceutical compositions containing such active ingredients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0209905A FR2843125B1 (fr) 2002-08-02 2002-08-02 Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs

Publications (2)

Publication Number Publication Date
FR2843125A1 FR2843125A1 (fr) 2004-02-06
FR2843125B1 true FR2843125B1 (fr) 2012-11-16

Family

ID=8871555

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0209905A Expired - Fee Related FR2843125B1 (fr) 2002-08-02 2002-08-02 Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs

Country Status (6)

Country Link
US (2) US20040091493A1 (fr)
JP (3) JP4824901B2 (fr)
KR (1) KR100697360B1 (fr)
DE (2) DE10251709C5 (fr)
FR (1) FR2843125B1 (fr)
GB (1) GB2391476B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2843125B1 (fr) * 2002-08-02 2012-11-16 Coletica Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs
JP4847756B2 (ja) * 2003-09-19 2011-12-28 大塚製薬株式会社 ヒトβディフェンシン分泌促進剤
WO2005073017A1 (fr) * 2004-02-02 2005-08-11 Daihatsu Motor Co., Ltd. Siege automobile
FR2869541B1 (fr) 2004-04-30 2007-12-28 Expanscience Sa Lab Utilisation d'une composition comprenant du d-mannoheptulose et/ou du perseitol dans le traitement et la prevention des maladies liees a une modification de l'immunite innee
US7258878B2 (en) 2004-12-20 2007-08-21 Kimberly-Clark Worldwide, Inc. Anti-microbial composition and methods of use thereof
US9284274B2 (en) 2005-12-07 2016-03-15 Ramot At Tel-Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
JP5464856B2 (ja) * 2005-12-07 2014-04-09 ラモト アット テル − アビブ ユニバーシティー リミテッド ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法
IL176608A0 (en) * 2006-06-28 2006-10-31 Lycored Ltd Compositions and methods for treating and preventing gastro esophageal reflux disease
DE602007005664D1 (de) * 2006-09-18 2010-05-12 Seppic Sa Verwendung eines quinoa-extrakts als kosmetisches und pharmazeutisches schlankheitsmittel und/oder als mittel zur verhinderung der formierung neuer fette im menschlichen körper
FR2905860B1 (fr) * 2006-09-18 2008-10-17 Seppic Sa Utilisation d'un extrait de quinoa comme actif cosmetique et pharmaceutique amincissant
FR2905861B1 (fr) * 2006-09-18 2008-10-17 Seppic Sa Utilisation d'un extrait de quinoa comme actif prevenant la formation de nouvelles graisses dans le corps humain
ES2621018T3 (es) 2007-02-19 2017-06-30 Marine Polymer Technologies, Inc. Composiciones hemostáticas y regímenes terapéuticos
FR2916634B1 (fr) * 2007-06-01 2009-10-02 Jean Noel Thorel Association synergique vis-a-vis de la flore microbienne de l'epiderme humain et applications cosmetiques et pharmaceutiques
FR2921254B1 (fr) * 2007-09-21 2009-11-13 Oreal Utilisation en depigmentation d'une association d'acide jasmonique et d'acide ascorbique
FR2929511B1 (fr) 2008-04-02 2010-12-31 Basf Beauty Care Solutions France Sas Nouveau principe actif stimulant la proliferation et/ou l'activite des fibroblastes.
KR100991293B1 (ko) 2008-08-11 2010-11-01 (주)바이오에프디엔씨 신규한 인간 베타 디펜신 유사 항균 펩타이드 및 이의 아토피 피부염 개선 소재로서의 활용
US8440237B2 (en) 2009-04-27 2013-05-14 Mary Kay Inc. Botanical anti-acne formulations
US9284252B2 (en) 2009-06-09 2016-03-15 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
DE102009044970A1 (de) 2009-07-23 2011-01-27 Henkel Ag & Co. Kgaa Verwendung von humanem beta-Defensin zur Beeinflussung des natürlichen Pigmentierungsprozesses
DE102009029110A1 (de) * 2009-09-02 2011-03-03 Henkel Ag & Co. Kgaa Antimikrobielle Formulierung
GB0920846D0 (en) 2009-11-27 2010-01-13 Croda Int Plc Defenin inducing agent
FR2953722B1 (fr) * 2009-12-16 2012-03-09 Expanscience Lab Composition comprenant au moins un sucre en c7 pour le traitement de l'alopecie, pour le traitement cosmetique des phaneres, et pour le soin des cheveux, cils ou ongles
JP2011168555A (ja) * 2010-02-22 2011-09-01 Pola Chemical Industries Inc 鑑別方法
WO2011130646A1 (fr) 2010-04-15 2011-10-20 Marine Polymer Technologies, Inc. Applications antibactériennes de nanofibres de poly-n-acétylglucosamine
BR112012029739A2 (pt) * 2010-05-24 2016-08-09 Indena Spa polissacarídeo da semente de tamarindo para uso no tratamento de infecções microbianas
JP6266857B2 (ja) * 2010-09-21 2018-01-24 共栄化学工業株式会社 化粧料
EA201391043A1 (ru) * 2011-02-17 2014-03-31 Сентисс Фарма Прайвет Лимитед Способ и композиция для замедления сорбции консервантов пластиками
AU2012242479B2 (en) 2011-04-15 2015-04-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
RU2453321C1 (ru) * 2011-05-03 2012-06-20 Общество с ограниченной ответственностью "ЛЕКВЕТ" (ООО "ЛЕКВЕТ") Препарат для лечения животных с противовоспалительным и антибактериальным действиями
CA2843636A1 (fr) * 2011-07-29 2013-02-07 Fred Hutchinson Cancer Research Center Methodes et compositions modulant la reponse immunitaire naturelle et/ou la myogenese chez un mammifere
US9138401B2 (en) 2011-12-19 2015-09-22 Mary Kay Inc. Combination of plant extracts to improve skin tone
JP2013010796A (ja) * 2012-10-15 2013-01-17 Kao Corp Ｓ１００ａ８発現調節剤
CN102988979B (zh) * 2012-12-13 2014-05-07 北京新华联协和药业有限责任公司 蒿属花粉变应原疫苗含片及其制备方法
US9511144B2 (en) 2013-03-14 2016-12-06 The Proctor & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives
JP6364281B2 (ja) * 2013-09-10 2018-07-25 花王株式会社 皮膚老化予防又は改善剤
WO2015093661A1 (fr) * 2013-12-19 2015-06-25 (주)바이오에프디엔씨 Dérivé longue durée par fusion à l'acide laurique de peptide antibactérien bêta-défensine 3 et 3h, mise au point de dérivé apte à traverser la peau par fusion de peptide transmissif aux cellules, et composition cosmétique le contenant
FR3015898B1 (fr) 2013-12-31 2016-02-05 Virbac Sa Composition topique comprenant des extraits de boldo et de reine des pres, destinee a un animal, et ses applications
EP3116469B1 (fr) 2014-03-10 2018-10-03 Mary Kay, Inc. Compositions d'éclaircissement de la peau
JP6407848B2 (ja) * 2015-01-14 2018-10-17 御木本製薬株式会社 ディフェンシン産生促進剤、カテリシジン産生促進剤、抗菌剤
US11020452B2 (en) * 2015-12-15 2021-06-01 Medicell Technologies, Llc Stem cell stimulating compositions and methods of treating melasma
WO2017173240A1 (fr) * 2016-03-31 2017-10-05 Gojo Industries, Inc. Composition nettoyante stimulant les peptides antimicrobiens
WO2017173236A1 (fr) * 2016-03-31 2017-10-05 Gojo Industries, Inc. Composition désinfectante de stimulation de peptides antimicrobiens
AU2017240069B2 (en) 2016-03-31 2024-03-07 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
EP3544575A1 (fr) 2016-11-23 2019-10-02 GOJO Industries, Inc. Composition désinfectante comprenant une substance active probiotique/prébiotique
JP7138496B2 (ja) * 2018-07-06 2022-09-16 花王株式会社 抗菌ペプチド発現促進剤
KR102524684B1 (ko) * 2022-09-05 2023-04-21 주식회사 래디안 피부의 방어 기능을 증진시키는 화장료 조성물
CN116251050B (zh) * 2023-05-09 2023-08-01 四平名居红酒庄园有限公司 一种葡萄籽红酒面膜泥的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3062721A (en) * 1957-03-20 1962-11-06 Grate Lorene Grigsby Skin care lotion
US3961054A (en) * 1973-01-22 1976-06-01 Ciba-Geigy Corporation Combatting dandruff with mercapto quinoline N-oxides
LU81257A1 (fr) * 1979-05-15 1980-12-16 Oreal Composition cosmetique pour le traitement des cheveux et de la peau,contenant un extrait de salsepareille
US4448714A (en) * 1979-10-12 1984-05-15 Cunliffe William J Antibiotic polypeptide compounds prepared from staphlococcus bacteria
LU83173A1 (fr) * 1981-02-27 1981-06-05 Oreal Nouvelles compositions cosmetiques pour le traitement des cheveux et de la peau contenant une poudre resultant de la pulverisation d'au moins une plante et un agent de cohesion
HU190813B (en) * 1982-10-07 1986-11-28 Valyi,Gabriella,Hu Process for producing cosmetic for aftertreating seborrhoeic and acneic processes
US4581351A (en) * 1982-11-23 1986-04-08 Sutton Laboratories, Inc. Composition of matter containing imidazolidinyl urea and pyrithione and its derivatives
DE3319184A1 (de) 1983-05-27 1984-11-29 Henkel Kgaa Verfahren zur abtrennung von allergenen aus arnikablueten mittels co(pfeil abwaerts)2(pfeil abwaerts)-hochdruckextraktion
US4849214A (en) * 1985-02-12 1989-07-18 Ruiseco Mario G Oil based scalp treatment composition
JPS6253917A (ja) * 1985-09-02 1987-03-09 Shiseido Co Ltd 頭髪化粧料
JPS62148427A (ja) * 1985-12-23 1987-07-02 Kao Corp 皮膚外用剤
US5084270A (en) * 1988-04-22 1992-01-28 Revlon, Inc. Cosmetic compositions containing N-alkoxyalkylamides
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
US5053222A (en) * 1989-06-07 1991-10-01 Shiseido Company Ltd. Hair cosmetic composition
US6350784B1 (en) * 1996-02-12 2002-02-26 Meryl J. Squires Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
JPH05331041A (ja) * 1992-05-29 1993-12-14 Tsuneo Nanba 美白化粧料
WO1994001074A1 (fr) * 1992-07-13 1994-01-20 Shiseido Company, Ltd. Composition de preparation dermatologique
JPH06227960A (ja) * 1993-02-01 1994-08-16 Yakult Honsha Co Ltd メラニン生成抑制剤および皮膚化粧料
FR2714602B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition antiacnéique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation.
JP3922594B2 (ja) * 1996-03-19 2007-05-30 株式会社ノエビア 抗菌性低刺激化粧料
EP0915693B1 (fr) * 1996-08-02 2003-10-01 Plum Kemi Produktion A/S Emulsion huile dans l'eau servant au nettoyage, a la protection ou a l'amelioration de l'etat de la peau humaine
AUPO427596A0 (en) * 1996-12-20 1997-01-23 Cooperative Research Centre For Tropical Plant Pathology Anti-microbial protein
JP4309972B2 (ja) * 1997-03-26 2009-08-05 雪印乳業株式会社 静菌及び抗菌剤
FR2765109B1 (fr) * 1997-06-25 2001-02-09 Seppic Sa Composition comprenant un lipoaminoacide et les constituants d'un extrait de plantes riches en tanins et utilisation en cosmetique
JP4061675B2 (ja) * 1997-09-02 2008-03-19 王子製紙株式会社 天然物由来の抗菌剤
JPH11286496A (ja) * 1997-12-22 1999-10-19 Morinaga & Co Ltd 抗菌ペプチド誘導及び／又は増強因子
US6984622B2 (en) * 1998-03-25 2006-01-10 The Regents Of The University Of California Use of lipopolysaccharides to manage corneal infections and wounds
WO1999049876A2 (fr) * 1998-03-31 1999-10-07 Abbott Laboratories Extraits bacteries ou de levures stimulant la production de defensines, et leur utilisation
AU4007699A (en) * 1998-05-21 1999-12-06 Mark Anderson A method for stimulation of defensin production by exposure to isoleucin
JP4132351B2 (ja) * 1999-02-10 2008-08-13 株式会社資生堂 抗プラスミン剤
US6887846B2 (en) * 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
JP2000336024A (ja) * 1999-05-27 2000-12-05 Ichimaru Pharcos Co Ltd 保湿性植物抽出物を含有する化粧料組成物
JP2001064192A (ja) * 1999-08-25 2001-03-13 Sunstar Inc ランゲルハンス細胞の遊走抑制剤及び抗原提示抑制剤
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
JP2001220313A (ja) * 2000-02-09 2001-08-14 Ichimaru Pharcos Co Ltd 植物水蒸気蒸留水含有化粧料組成物
WO2001068085A1 (fr) * 2000-03-15 2001-09-20 Genaera Corporation Procede permettant de stimuler la production de defensine
FR2807319B1 (fr) 2000-04-07 2004-10-22 L M D Composition cosmetique ou en tant que medicament contenant une lactone sesquiterpenique pour traiter les hematomes, et procede de traitement
JP4814415B2 (ja) * 2000-05-29 2011-11-16 一丸ファルコス株式会社 化粧料組成物
WO2001092309A2 (fr) * 2000-06-01 2001-12-06 University Of Iowa Research Foundation Defensine humaine beta 3 (hbd-3), peptide antimicrobien hautement cationique de la defensine beta
DE60114122T2 (de) * 2000-06-23 2006-07-13 Sakai, Takuo, Sakai Verfahren zur herstellung einer aus pflanzen stammenden, antibakteriellen substanz
RU2180210C1 (ru) * 2000-07-26 2002-03-10 Закрытое акционерное общество "Компания КОРА" Косметическое средство для ухода за волосами
JP2002186485A (ja) * 2000-12-22 2002-07-02 Shiseido Co Ltd エオタキシン、ＲＡＮＴＥＳ又はβ−ディフェンシン−２の核酸の測定方法及びそのための試薬、並びに抗炎症剤のスクリーニング方法
JP2002212009A (ja) * 2001-01-18 2002-07-31 Noevir Co Ltd 抗かび剤、及びこれを含有して成る抗菌性低刺激化粧料
JP2002226403A (ja) * 2001-02-01 2002-08-14 Mareyoshi Sawaguchi 口腔用及び皮膚科用剤の添加剤
JP2002241303A (ja) * 2001-02-13 2002-08-28 Hisamitsu Pharmaceut Co Inc Ｅｔｓ転写因子又はそれをコードする遺伝子からなる上皮細胞のｇｍ−ｃｓｆ、及び／又はディフェンシン蛋白質の発現調節剤。
DE10111288A1 (de) * 2001-03-09 2002-09-12 Wella Ag Antischuppenmittel
JP2002363065A (ja) * 2001-06-04 2002-12-18 Satoru Murakami 薬草化粧石鹸及びローション
FR2843125B1 (fr) * 2002-08-02 2012-11-16 Coletica Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs

Also Published As

Publication number Publication date
DE10251709A1 (de) 2004-02-12
KR20040012426A (ko) 2004-02-11
JP5226257B2 (ja) 2013-07-03
JP4824901B2 (ja) 2011-11-30
GB0225886D0 (en) 2002-12-11
GB2391476A (en) 2004-02-11
JP2008019264A (ja) 2008-01-31
DE10251709B4 (de) 2008-11-27
FR2843125A1 (fr) 2004-02-06
JP2004067660A (ja) 2004-03-04
US20040091493A1 (en) 2004-05-13
KR100697360B1 (ko) 2007-03-20
US20160361250A1 (en) 2016-12-15
GB2391476B (en) 2006-12-20
DE10262193B4 (de) 2019-06-27
DE10251709C5 (de) 2011-02-24
JP2012250992A (ja) 2012-12-20

Similar Documents

Publication Publication Date Title
FR2843125B1 (fr) Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs
FR2834718B1 (fr) Substances actives cosmetiques et/ou pharmaceutiques
DE50211581D1 (de) Tensidefreie kosmetische, dermatologische und pharmazeutische Mittel
ITMI20020399A0 (it) Composizioni dietetiche e/o farmaceutiche per uso umano e/o animale abase di preparati microbici probiotici
BR0311313A (pt) Derivados de diaril uréia úteis para o tratamento de doenças dependentes de proteìna cinase
EP2377543A3 (fr) Préparations ophtalmiques, pharmaceutiques et de soins de santé contenant des composes, des extraits et des derives naturels d'origine végétale
HUP0104258A2 (hu) HMG-CoA reduktáz inhibítort tartalmazó stabil gyógyszerkészítmények
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
BR0115810B1 (pt) composições cosméticas, dermatológicas e farmacêuticas isentas de tensoativos.
PT1207756E (pt) Utilizacao de espinosade ou de uma formulacao que compreende espinosade
AU2002342765A1 (en) Active ingredient combinations of polyhexamethylenebiguanidine hydrochloride and distearyldimethylammonium chloride and preparations comprising said active ingredient combinations
FR2863893B1 (fr) Utilisation de principes actifs stimulant les beta-defensines humaines de type 2 et/ou de type 3
WO2005103102A8 (fr) Copolymere sequence
EP0824915A3 (fr) Préparation de glycoglycerolipides, leur utilisation comme agents tensio-actifs et compositions cosmétiques ou dermatologiques les contenant
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
FR2787996B1 (fr) Composition cosmetique ou dermatologique contenant un actif stimulant la synthese de la proteine hsp 32 dans la peau et methode de traitement cosmetique
FR2744452B1 (fr) Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
PT1147105E (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente activo e sua utilizacao no tratamento de doencas vasculares
WO2002070741A3 (fr) Procedes, systemes et produits programmes informatiques permettant de determiner l'effet biologique et/ou l'activite de medicaments, de substances chimiques et/ou de compositions pharmaceutiques, sur la base de leur effet sur l'etat de methylation de l'adn
FR2845388B1 (fr) Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
FR2821551B1 (fr) Utilisations de derives de polyaminoacides comme agents hydratants, et compositions cosmetiques ou pharmaceutiques les comprenant
DE60135390D1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
SE0001916D0 (sv) Novel formulation
HUP0402092A2 (hu) 2-[5-(4-Fluorfenil)-3-piridilmetilaminometil]-kromán vegyületek és fiziológiásan elfogadható sói alkalmazása gyógyszerkészítmények előállítására
WO2001080891A8 (fr) Substances medicamenteuses destinees a la pneumonie interstitielle, procede de construction d'un modele animal de cette maladie et procede de criblage dans lequel on utilise ce dernier

Legal Events

Date Code Title Description
CD Change of name or company name
TQ Partial transmission of property
PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

ST Notification of lapse

Effective date: 20220405